| Keywords: |
cancer survival; exon; gene deletion; mutation; fatigue; cisplatin; erlotinib; placebo; cancer combination chemotherapy; diarrhea; dose response; drug dose reduction; drug efficacy; drug safety; drug withdrawal; side effect; treatment planning; unspecified side effect; drug approval; gemcitabine; antineoplastic agent; metastasis; progression free survival; lung non small cell cancer; mucosa inflammation; nausea; carcinoma, non-small-cell lung; lung neoplasms; epidermal growth factor receptor; lung cancer; receptor, epidermal growth factor; drug potency; substitution reaction; cetuximab; protein tyrosine kinase inhibitor; coughing; dyspnea; rash; drug cost; dysphagia; lung adenocarcinoma; gefitinib; nail; short survey; clinical effectiveness; large cell carcinoma; lung squamous cell carcinoma; platinum complex; egfr gene; dry skin; quinazolines; pemetrexed; mouth pain; drug indication; molecular targeted therapy; afatinib; humans; human; priority journal
|
